By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -A boardroom shake-up at Novo Nordisk has handed ...

In the latest close session, Novo Nordisk (NVO) was down 1.59% at $52.05. The stock trailed the S&P 500, which registered a daily gain of 0.23%. On the other hand, the Dow registered a gain of 0.34%, ...

Novo Nordisk today announced plans to present 11 abstracts at the 76th Annual American Association for the Study of Liver ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

Novo Nordisk is undergoing significant leadership changes, including the replacement of its chair and six independent ...

Novo Nordisk will replace chair Helge Lund and six independent directors next month in a major boardroom shakeup following a ...

Shares of Novo Nordisk have dropped as the company's largest investor, Novo Nordisk Foundation, calls for a board overhaul.

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

It was a deal with the Danish drugmaker that markets Ozempic and Wegovy that moved Omeros' stock price. Novo Nordisk ( NVO ...

Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the ...

Omeros OMER stock surged 149% after announcing a $2.1 billion licensing deal with Novo Nordisk for its experimental drug ...